Naperville, IL -- (SBWIRE) -- 08/07/2014 -- Reportstack, provider of premium market research reports announces the addition of Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014 market report to its offering.
DelveInsights,Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Anti-CD279 (PD-1) Antibody. This report provides information on the therapeutic development based on the Anti-CD279 (PD-1) Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.
The report provides a snapshot of the global therapeutic landscape of Anti-CD279 (PD-1) Antibody
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the Anti-CD279 (PD-1) Antibody pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Anti-CD279 (PD-1) Antibody and also provide company profiling
The report also gives the information of dormant and discontinued pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy
Complete MOA intelligence and complete understanding over therapeutics development for Anti-CD279 (PD-1) Antibody
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Anti-CD279 (PD-1) Antibody pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
To view the table of contents for this market research report please visit